ConductScience.org, home

Paper42972049PubMed

A multi-institutional investigation of psilocybin's effects on mouse behavior.

Lu OD and 29 others. Nat Neurosci, 2026.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. A multi-institutional investigation of psilocybin's effects on mouse behavior. Papers, record 42972049. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42972049

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A multi-institutional investigation of psilocybin's effects on mouse behavior.
Journal
Nat Neurosci
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-11-02

Source PubMed

Authors30

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lu ODOdilia Dhttps://orcid.org/0000-0003-0928-0144
2White KKatrina
3Raymond KBKendall B
4Liu CChristine
5Klein ASAlexandra Shttps://orcid.org/0000-0002-0997-3648
6Green NNathanielhttps://orcid.org/0009-0005-2980-5333
7Vaillancourt SSamhttps://orcid.org/0009-0007-2220-9998
8Gallagher AJAustin J
9Shindy LLena
10Li AAlyssa
11Wallquist KEKira E
12Li RRuoxian
13Zou MMila
14Casey ABAusten Bhttps://orcid.org/0000-0002-4670-851X
15Perez NNatalie
16Asim MMuhammadhttps://orcid.org/0000-0002-6912-4461
17Metanat SSetareh
18Logas KRKelsey R
19Chhaya VVivan
20Enos ASAlexander S

Source PubMed

See all 30 authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P50 DA042012U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)P50DA042012PubMedNIH RePORTER
K99 DA056573U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)K99DA056573PubMedNIH RePORTER
P50 DA042012U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)P50DA042012PubMedNIH RePORTER
K08 DA055157U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)K08DA055157PubMedNIH RePORTER
K12GM081266U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)K12GM081266PubMedNIH RePORTER

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127,210,031Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.Lancet Psychiatry2016https://conductscience.org/library/papers/27210031PubMed
237,651,119Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.JAMA2023https://conductscience.org/library/papers/37651119PubMed
336,322,843Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.N Engl J Med2022https://conductscience.org/library/papers/36322843PubMed
427,909,165Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.J Psychopharmacol2016https://conductscience.org/library/papers/27909165PubMed
527,909,164Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.J Psychopharmacol2016https://conductscience.org/library/papers/27909164PubMed
625,213,996Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.J Psychopharmacol2014https://conductscience.org/library/papers/25213996PubMed
725,586,396Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.J Psychopharmacol2015https://conductscience.org/library/papers/25586396PubMed
833,972,795MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.Nat Med2021https://conductscience.org/library/papers/33972795PubMed
937,709,999MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.Nat Med2023https://conductscience.org/library/papers/37709999PubMed
1040,906,494Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.JAMA2025https://conductscience.org/library/papers/40906494PubMed
1124,594,678Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.J Nerv Ment Dis2014https://conductscience.org/library/papers/24594678PubMed
1238,182,784Magnesium-ibogaine therapy in veterans with traumatic brain injuries.Nat Med2024https://conductscience.org/library/papers/38182784PubMed
1328,402,682Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.Am J Drug Alcohol Abuse2018https://conductscience.org/library/papers/28402682PubMed
1437,734,158Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.Am J Drug Alcohol Abuse2023https://conductscience.org/library/papers/37734158PubMed
1533,852,780Trial of Psilocybin versus Escitalopram for Depression.N Engl J Med2021https://conductscience.org/library/papers/33852780PubMed
1627,568,263Psilocybin: panacea or placebo?Lancet Psychiatry2016https://conductscience.org/library/papers/27568263PubMed
1737,588,757Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice.ACS Pharmacol Transl Sci2023https://conductscience.org/library/papers/37588757PubMed
1833,850,049Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.Proc Natl Acad Sci U S A2021https://conductscience.org/library/papers/33850049PubMed
1937,874,338Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.Naunyn Schmiedebergs Arch Pharmacol2024https://conductscience.org/library/papers/37874338PubMed
2031,106,729Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat.Acta Neuropsychiatr2019https://conductscience.org/library/papers/31106729PubMed

See all 62 references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42972049

GET https://conductscience.org/api/papers/v1/42972049/authors?page=2